- Being able to carry out an oversubscribed share issue in today’s market means a great deal to us, says Ulf Hannelius, CEO of Diamyd Medical. It shows that our vision is shared by many and also serves as a testament to the progress we have made over the past year. I would like to extend a heartfelt thank you to all shareholders who believe in us and our work. Thanks to this resource-efficient capital raise, we now have the financial resilience to carry us all the way to the Phase 3 results in March 2026.

The Board of Directors in Diamyd Medical resolved on February 28, 2025, pursuant to the authorization granted by the Company's annual general meeting held on December 5, 2024, on a rights issue of up to approximately SEK 208 million.

Final Outcome
The Rights Issue was comprised of 26,024,624 units, of which 389,624 A-units and 15,597,393 B-units, corresponding to approximately 61 percent of the offered units, have been subscribed for with unit rights. Additionally, applications for subscription of 12,014,210 B-units without unit rights, corresponding to approximately 46 percent of the offered units, have been received. Thus, the subscriptions by exercise of unit rights and the applications for subscription without unit rights correspond to approximately 108 percent. Through the Rights Issue, the Company will thus receive issue proceeds of approximately SEK 205 million before the deduction of costs attributable to the Rights Issue. The Rights Issue is not subject to costs for underwriting commitments.

Exercise of the Additional Unit Issue
In connection with the Company’s announcement on February 28, 2025, that the Board of Directors had resolved on the Rights Issue, the Board of Directors also communicated its intention to resolve on an additional unit issue of up to 2,500,000 B-units, corresponding to additional issue proceeds of up to SEK 20 million, in the event that the B-units offered in the Rights Issue were fully subscribed. The purpose was to meet a higher-than-anticipated demand and to provide the Company with additional capital. Due to the strong interest in the Rights Issue, the Board of Directors have today resolved, pursuant to the authorization granted by the Company's annual general meeting held on December 5, 2024, on the Additional Unit Issue without preferential rights up to the amount subscribed in excess of the full subscription of the total amount of B-units offered in the Rights Issue. Consequently, a total of 2,334,103 B-units will be issued in the Additional Unit Issue.

After a comprehensive assessment and careful consideration as to whether there are sufficient reasons to deviate from the shareholders’ preferential rights, the Board of Directors believes that carrying out the Additional Unit Issue without preferential rights is a better alternative for the Company and its shareholders, as it provides the Company with additional working capital to expand preparations for a potential market approval, with a relatively limited dilution, in a time-efficient and cost-effective manner. The Board of Directors thus assess it to be in the interests of both the Company and its shareholders to proceed with the Additional Unit Issue. The Board of Directors’ overall assessment is therefore that the reasons for conducting the Additional Unit Issue outweigh the reasons underlying the main rule that new share issues shall be carried out with preferential rights for shareholders. The subscription price in the Additional Unit Issue will correspond to the subscription price in the Rights Issue, i.e., SEK 8 per unit, equivalent to SEK 8 per share (the warrants are issued free of charge). By virtue of the Additional Unit Issue, the Company will receive additional issue proceeds of approximately SEK 19 million before deduction of related issue costs, and thus the total issue will increase to approximately SEK 224 million before related issue costs.

Notice of allotment
All those who have subscribed for units without unit rights will be allocated units in accordance with the principles set out in the EU growth prospectus which was approved and registered by the Swedish Financial Supervisory Authority on April 14, 2025. Notice of allotment to the persons who subscribed for units without unit rights is expected to be distributed on May 2, 2025. Subscribed and allotted units shall be paid in cash within three banking days in accordance with the instructions on the settlement note sent to the subscriber. Subscribers who have subscribed for units through a nominee will receive notification of allocation in accordance with their respective nominee’s procedures. Only those who have been allotted units will be notified.

Number of shares and share capital
Through the Rights Issue, Diamyd Medical’s share capital will increase by SEK 2,639,450.1502, from SEK 10,557,800.6008 to SEK 13,197,250.7510, and the number of shares will increase by 26,024,624 shares, from 104,098,496 shares to 130,123,120 shares, resulting in that the number of A-shares after the Rights Issue will amount to 3,735,620 and the number of B-shares will amount to 126,387,500. As a result of the Additional Unit Issue, the share capital will increase by an additional SEK 236,727.6666, from SEK 13,197,250.7510 to SEK 13,433,978.4176, and the number of shares will increase by 2,334,103 shares, from 130,123,120 shares to 132,457,223 shares, resulting in that the number of A-shares after the Rights Issue and the Additional Unit Issue will amount to 3,735,620 and the number of B-shares will amount to 128,721,603.

The last day of trading in paid subscribed units (Sw. BTU B) is expected to be May 20, 2025. The new B-shares and TO 5 B subscribed for with and without unit rights are expected to be traded on Nasdaq First North Growth Market around May 26, 2025.

Advisors
G&W Fondkommission acts as Financial Advisor to Diamyd Medical in connection with the Rights Issue. Aqurat Fondkommission AB has been appointed as Issuer Agent.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes. Diamyd^{® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. An early read-out of the Phase 3 trial is expected in March 2026. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group – both in a largescale meta-analysis as well as in the Company’s prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.}

Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on April 30, 2025, 20.50 CET.

Important information
Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction.

The information in this press release does not contain or constitute an offer to acquire, subscribe for units or otherwise trade in units, unit rights or other securities in Diamyd Medical. The information contained in this press release is for background purposes only and does not purport to be full or complete. This press release does not identify, or purport to identify, risks (direct or indirect) that may be associated with an investment in the Company. No reliance may be placed by any person for any purpose on the information contained in this press release or its accuracy, fairness, or completeness. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. A prospectus, equivalent to an EU growth prospectus, regarding the Rights Issue referred to in this press release have been prepared and published by the Company before the subscription period in the Rights Issue begun. Investors should not invest in any securities referred to in this press release except on the basis of information contained in the EU Growth Prospectus. Any invitation to those entitled to subscribe for units in Diamyd Medical is made solely through the EU growth prospectus which Diamyd Medical have published on April 14, 2025.

This press release or information herein may not, in whole or partly, be released, published or distributed, directly or indirectly, in or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what is required pursuant to Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No unit rights, paid subscribed units (BTU) or new shares and warrants have or will be registered under the United States Securities Act of 1933 (the “Securities Act”) or securities legislation in any state or other jurisdiction in the United States and may not be offered, subscribed, used, pledged, sold, resold, allotted, delivered or transferred, directly or indirectly, into or within the United States, other than pursuant to an exemption from, or in a transaction that is subject to, the registration requirements of the Securities Act. Furthermore, the securities mentioned in this press release have not been registered and will not be registered under any applicable securities law in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or Switzerland and may, with certain exceptions, not be offered or sold within, or on behalf of a person or for the benefit of a person who is registered in, these countries or any other jurisdiction in which the release, distribution or publication would be unlawful or require registration or any other measure. The Company has not made an offer to the public to subscribe for or acquire the securities mentioned in this press release in any jurisdiction other than in Sweden.

In the EEA Member States, with the exception of Sweden, (each such EEA Member State, a “Relevant State“), this press release and the information contained herein are intended only for and directed to qualified investors as defined in the Prospectus Regulation. The securities mentioned in this press release are not intended to be offered to the public in any Relevant State and are only available to qualified investors except in accordance with exceptions in the Prospectus Regulation. Persons in any Relevant State who are not qualified investors should not take any actions based on this press release, nor rely on it.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements
This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as ”believe”, ”expect”, ”anticipate”, ”intend”, ”may”, ”plan”, ”estimate”, ”will”, ”should”, ”could”, ”aim” or ”might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq First North Growth Market rule book for issuers.